Business Context and Reporting Period
The provided filing is a Form 10-Q for Brooks Automation, Inc., not Azenta, Inc. It covers the quarter and six months ended March 31, 2012, Brooks’ fiscal second quarter. The filing describes automation, vacuum, instrumentation, global services, and life-science systems businesses. Semiconductor capital equipment represented approximately 55% of first-half fiscal 2012 revenue.
Key Financial Metrics
| Metric | Three months ended March 31, 2012 | Prior year | Six months ended March 31, 2012 | Prior year |
|---|---|---|---|---|
| Revenue | $139.3 million | $192.7 million | $259.6 million | $371.0 million |
| Gross profit | $48.3 million | $61.7 million | $88.6 million | $119.0 million |
| Gross margin | 34.7% | 32.0% | 34.1% | 32.1% |
| Operating income | $8.4 million | $26.7 million | $9.9 million | $50.5 million |
| Net income attributable to Brooks | $9.5 million | $26.6 million | $12.5 million | $50.1 million |
| Diluted EPS | $0.14 | $0.41 | $0.19 | $0.77 |
| EBITDA | $13.9 million | $31.4 million | $22.2 million | $59.9 million |
| Adjusted EBITDA | $20.6 million | $34.1 million | $31.4 million | $64.0 million |
Six-month operating cash flow was $21.7 million, compared with $38.9 million in the prior year. Capital expenditures were $4.4 million, and cash used for dividends was $10.4 million. Cash and cash equivalents increased to $81.2 million from $58.8 million at September 30, 2011. Including marketable securities, liquidity was approximately $204.3 million.
At March 31, 2012, total assets were $636.7 million and total liabilities were $114.4 million. The balance sheet reports no borrowings or debt balance. Pension, warranty, tax, restructuring, and other liabilities remained outstanding.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue declined 28%; first-half revenue declined 30%. The Contract Manufacturing business sale reduced comparable revenue by $49.1 million in the quarter and $95.0 million in the first half.
- Lower semiconductor and adjacent-market demand reduced revenue by $18.2 million in the quarter and $44.9 million in the first half. Management stated that recent semiconductor capital-equipment demand had improved.
- Gross margin increased because the lower-margin Contract Manufacturing segment was sold and higher-margin life-science operations were added. Product Solutions and Global Services segment margins nevertheless declined because of unfavorable mix, lower volumes, excess and obsolete inventory charges, and under-absorption of fixed costs.
- Operating income and EPS fell materially because of lower revenue, higher research and development costs, acquired-business expenses, and a $3.0 million in-process research and development charge related to intellectual property acquired from Intevac.
- Research and development expense increased to $12.5 million from $9.4 million for the quarter and to $24.5 million from $18.3 million for the first half.
- SG&A included a favorable $3.3 million reduction from insurance proceeds related to prior litigation costs.
Guidance, Outlook, Risks, and Unusual Items
- Management expected improved semiconductor capital-equipment demand to produce higher near-term revenue than in the first half of fiscal 2012, but provided no specific numerical revenue or earnings guidance.
- The company considers semiconductor demand cyclical, making longer-term revenue and cash-flow forecasts uncertain. It stated that adequate resources were available for planned requirements over the next twelve months.
- Brooks acquired the Celigo cell-cytometer product line for $8.7 million in cash plus a $0.5 million deferred payment. The acquisition added $3.7 million of goodwill and was integrated into the Life Science Systems segment.
- The company incurred a $3.0 million in-process research and development charge for the Intevac intellectual-property acquisition.
- Restructuring charges were $42,000 for the quarter and $245,000 for the first half, primarily for limited workforce reductions responding to weaker demand.
- Brooks intended to settle the frozen Helix pension obligation during fiscal 2012, requiring approximately $6 million of cash payments and potentially accelerating approximately $8 million of previously unrecognized pension losses.
- The company maintained a full valuation allowance against deferred tax assets. It stated that continued profitability could lead to a significant non-cash tax benefit from reducing the allowance.
- The company declared a subsequent quarterly dividend of $0.08 per share, approximately $5.2 million in total, payable June 29, 2012.
- Two customers represented 16% and 10% of quarterly revenue, indicating customer-concentration risk. Foreign-currency exposure included approximately $14.5 million of intercompany advances; management estimated that a 10% currency movement could change net income by approximately $1.5 million.
- Legal proceedings related to former executive Robert Therrien were substantially settled. The company recorded approximately $3.3 million of net insurance proceeds as a reduction of SG&A in the quarter.
Most Important Facts to Verify
- Verify the issuer identity: the supplied document is Brooks Automation’s 2012 Form 10-Q, not an Azenta filing.
- Verify whether revenue comparisons should be adjusted for the June 2011 sale of Contract Manufacturing and the RTS and Nexus acquisitions.
- Assess the sustainability of improved gross margin after excluding portfolio-mix benefits and considering lower Product Solutions and Global Services segment margins.
- Review semiconductor demand, customer concentration, and the effect of cyclicality on future revenue and cash flow.
- Confirm the timing and cash impact of the planned pension settlement, the Celigo deferred payment, and future dividends.
- Review the tax valuation allowance and potential non-cash tax benefit, as well as the company’s marketable-securities composition and interest-rate exposure.